Stock Market Reviews

INSM (Insmed Incorporated) News

Get the latest news, insights, and market updates on INSM (Insmed Incorporated). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Insmed Stock Plummets 19%. This Is What Sparked the Selloff.
  The biopharmaceutical company said it was discontinuing development of a drug treating a chronic sinus condition.
  Dec 18, 2025 - $INSM
• The 'Worst-Case Scenario' — Why Insmed Just Reversed After A 181% Six-Month Sprint
  Insmed stock crumbled Thursday after the highly rated biotech company scrapped one of its brensocatib studies.
  Dec 18, 2025 - $INSM
• Insmed Provides Clinical and Business Update
  Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, announced today that the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms. Brensocatib was well tolerated, with no new safety signals identified
  Dec 17, 2025 - $INSM
• 200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party
  Seagate, Western Digital lead a stunning reshuffle as tech laggards like Lululemon and Trade Desk get the boot.
  Dec 15, 2025 - $INSM
• Western Digital stock rises after inclusion in Nasdaq-100 Index
  Investing.com -- Western Digital Corp. (NASDAQ:WDC) stock rose 1.7% Monday following the announcement of its inclusion in the Nasdaq-100 Index as part of the annual reconstitution.
  Dec 15, 2025 - $INSM
• How Investors Are Reacting To Insmed (INSM) Joining The Nasdaq-100 Index
  Nasdaq recently confirmed that Insmed Incorporated will be added to the Nasdaq-100 Index, one of its flagship benchmarks of large non-financial companies, effective December 22, 2025. This index inclusion could broaden Insmed’s investor base as index-linked funds and institutional portfolios adjust their holdings to reflect the change. We’ll explore how joining the Nasdaq-100, and the increased index-tracking demand it may attract, could influence Insmed’s existing investment...
  Dec 15, 2025 - $INSM
• MicroStrategy retains place in key index despite delisting threats
  Michael Saylor's Bitcoin (BTC) treasury company, Strategy (Nasdaq: MSTR), earlier known as MicroStrategy, has been successful in retaining its spot in the Nasdaq 100 (NDQ). A benchmark stock market index in the U.S., the Nasdaq 100 tracks hundred of the largest non-financial ...
  Dec 15, 2025 - $INSM
• Annual Changes to the Nasdaq-100 Index®
  NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December 22, 2025. The following six companies will be added to the Index: Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), Ferrovial SE (Nasdaq: FER), Insmed Incorporated (Nasdaq: INSM), Monolithic Power Systems, Inc. (Nasdaq: MPWR), Seagate Technology Holdings plc (Nasdaq: STX), Weste
  Dec 13, 2025 - $INSM
• Bitcoin hoarding company Strategy remains in Nasdaq 100
  Bitcoin hoarding giant Strategy clung to its place in the Nasdaq 100 on ​Friday, continuing its year-long stint in the benchmark ‌at a time where analysts have raised questions over its business ‌model. Some market watchers have suggested Strategy's pioneering business model of buying-and-holding bitcoin, which has spawned dozens of copycats, more closely resembles that of an investment fund. Nasdaq said Biogen, ‍CDW Corporation, Globalfoundries, Lululemon Athletica, On Semiconductor and Trade Desk were removed from the tech-heavy exchange's benchmark index.
  Dec 13, 2025 - $INSM
• Is It Too Late to Consider Insmed After a 179% Surge and DCF Upside?
  If you are wondering whether Insmed is still worth buying after its massive run, or if the real upside has already been priced in, you are not alone. The stock has cooled slightly in the last week, down 4.8%, but that follows a powerful 179.1% year to date climb and a 903.3% gain over three years that has clearly reset market expectations. Moves of that magnitude usually follow meaningful milestones, such as advancing late stage respiratory drug candidates, receiving positive regulatory...
  Dec 12, 2025 - $INSM